Journal of Neuro-Oncology

, Volume 137, Issue 2, pp 241–248 | Cite as

Overexpression of aryl hydrocarbon receptor (AHR) signalling pathway in human meningioma

  • Noble Kumar Talari
  • Manas K. Panigrahi
  • Sailaja Madigubba
  • Prakash Babu PhanithiEmail author
Laboratory Investigation


Aryl hydrocarbon receptor (AHR) is a ligand activated transcription factor and involved in tumorigenesis of many cancers. However there are no reports on AHR in human meningioma. Therefore we examined the status of the AHR and its signalling molecules in human meningioma by using tumor biopsy samples and autopsy control meninges. We report the up regulation of AHR pathway genes like aryl hydrocarbon receptor nuclear translocator (ARNT), aldehyde dehydrogenase1family memberA3 (ALDH1A3), cytochrome P450, family1, subfamily A polypeptide1 (CYP1A1) and TCCD induced poly ADP ribose polymerase (TIPARP) gene expression in human meningioma. Further, AHR protein expression was found to be up regulated in all grades of human meningioma. We found that AHR localized in the nucleus for high grade anaplastic meningioma through immunohistochemical analysis. Since AHR signalling pathway was known to involve in inhibition of apoptosis in cancer cells, we evaluated the cyclophilin D levels which maintains mitochondrial permeability transition pore a critical event during apoptosis. We report that cyclophilin D levels were upregulated in all grades of human meningioma compared to control meninges. Finally we also evaluated c-Fos protein levels as its levels were regulated by AHR. Here we report that c-Fos protein levels were down regulated in all grades of human meningioma compared to control meninges. To sum-up we found that AHR signalling pathway components were upregulated, as the grade of the meningioma progresses from low to high grade, suggesting an important role of AHR signalling pathway in human meningioma.


Human meningioma Aryl hydrocarbon receptor (AHR) Kynurenine (KYN) Indoleamine 2, 3 dioxygenases (IDO) 



This work was supported by Grants from Department of Biotechnology [BT/PR18168/MED/29/1064/2016, BT/PR13111/MED/29/149/2009], Department of Science and Technology [SR/CSRI/196/2016, SB/EMEQ-257/2013], Universities with potential for excellence Phase II [UH/UPE-2/28/2015] New Delhi, Government of India. The authors wish to acknowledge help of Dr. Janaki, Kurnool Medical College, Andhra Pradesh-INDIA, for providing autopsy meninges for our study.

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest.

Supplementary material

11060_2017_2730_MOESM1_ESM.tif (1.1 mb)
Supplementary material 1 (TIF 1078 KB) Fig. S1 AHR (~ 100 kD) protein expression in human meningioma (a) AHR and GAPDH immuno-blots. b Densitometry analysis of AHR immunoblot. The expression levels of GAPDH (~ 38 kD) was used as loading controls. Data are represented as mean ± SE n = 6 for CM (Control meninges); n = 10 for GI (Grade I meningioma); n = 8 for GII (Grade II meningioma) and n = 6 for GIII (Grade III meningioma). pa ≤ 0.05; pb 0.05, pc ≤ 0.05 (where a, b, and c refers to comparison with CM, GI, GII respectively.


  1. 1.
    Barouki R, Coumoul X, Fernandez-Salguero PM (2007) The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett 581:3608–3615. CrossRefPubMedGoogle Scholar
  2. 2.
    Zhang S, Kim K, Jin UH, Pfent C, Cao H, Amendt B, Liu X, Wilson-Robles H, Safe S (2012) Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells. Mol Cancer Ther 11:108–118. CrossRefPubMedGoogle Scholar
  3. 3.
    Su JM, Lin P, Wang CK, Chang H (2009) Overexpression of cytochrome P450 1B1 in advanced non-small cell lung cancer: a potential therapeutic target. Anticancer Res 29:509–515PubMedGoogle Scholar
  4. 4.
    Fritz WA, Lin TM, Safe S, Moore RW, Peterson RE (2009) The selective aryl hydrocarbon receptor modulator 6-methyl-1, 3, 8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. Biochem Pharmacol 77:1151–1160. CrossRefPubMedGoogle Scholar
  5. 5.
    Callero MA, Suarez GV, Luzzani G, Itkin B, Nguyen B, Loaiza-Perez AI (2012) Aryl hydrocarbon receptor activation by aminoflavone: new molecular target for renal cancer treatment. Int J Oncol 41:125–134. CrossRefPubMedGoogle Scholar
  6. 6.
    Yin XF, Chen J, Mao W, Wang YH, Chen MH (2012) A selective aryl hydrocarbon receptor modulator 3, 30-Diindolylmethane inhibits gastric cancer cell growth. J Exp Clin Cancer Res 31:46. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Peng TL, Chen J, Mao W, Liu X, Tao Y, Chen LZ, Chen MH (2009) Potential therapeutic significance of increased expression of aryl hydrocarbon receptor in human gastric cancer. World J Gastroenterol 15:1719–1729CrossRefGoogle Scholar
  8. 8.
    Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478:197–203. CrossRefPubMedGoogle Scholar
  9. 9.
    Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA (2010) An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 185:3190–3198. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Talari NK, Panigrahi M, Madigubba S, Challa S, Phanithi PB (2016) Altered tryptophan metabolism in human meningioma. J Neurooncol. CrossRefPubMedGoogle Scholar
  11. 11.
    Perdew GH, Bradfield CA (1996) Mapping the 90 kDa heat shock protein binding region of the Ah receptor. Biochem Mol Biol Int 39:589–593PubMedGoogle Scholar
  12. 12.
    Kazlauskas A, Poellinger L, Pongratz I (1999) Evidence that the co-chaperone p23 regulates ligand responsiveness of the dioxin (Aryl hydrocarbon) receptor. J Biol Chem 274:13519–13524CrossRefGoogle Scholar
  13. 13.
    Enan E, Matsumura F (1996) Identification of c-Src as the integral component of the cytosolic Ah receptor complex, transducing the signal of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) through the protein phosphorylation pathway. Biochem Pharmacol 52:1599–1612CrossRefGoogle Scholar
  14. 14.
    Kim S, Dere E, Burgoon LD, Chang CC, Zacharewski TR (2009) Comparative analysis of AhR-mediated TCDD-elicited gene expression in human liver adult stem cells. Toxicol Sci 112:229–244. CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Duan JJ, Cai J, Guo YF, Bian XW, Yu SC (2016) ALDH1A3, a metabolic target for cancer diagnosis and therapy. Int J Cancer 139:965–975. CrossRefPubMedGoogle Scholar
  16. 16.
    Whitlock JP Jr (1999) Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 39:103–125. CrossRefPubMedGoogle Scholar
  17. 17.
    Leung YK, Lau KM, Mobley J, Jiang Z, Ho SM (2005) Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res 65:3726–3734. CrossRefPubMedGoogle Scholar
  18. 18.
    Rodriguez M, Potter DA (2013) CYP1A1 regulates breast cancerproliferation and survival. Mol Cancer Res 11:780–792. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Zaher H, Fernandez-Salguero PM, Letterio J, Sheikh MS, Fornace AJ Jr, Roberts AB, Gonzalez FJ (1998) The involvement of aryl hydrocarbon receptor in the activation of transforming growth factor-beta and apoptosis. Mol Pharmacol 54:313–321CrossRefGoogle Scholar
  20. 20.
    Schubert A, Grimm S (2004) CyclophilinD, a component of the permeability transition-pore, is an apoptosis repressor. Cancer Res 64:85–93CrossRefGoogle Scholar
  21. 21.
    Mejía-García A, González-Barbosa E, Martínez-Guzmán C, Torres-Ramos MA, Rodríguez MS, Guzmán-León S, Elizondo G (2015) Activation of AHR mediates the ubiquitination and proteasome degradation of c-Fos through the induction of Ubcm4 gene expression. Toxicology 337:47–57. CrossRefPubMedGoogle Scholar
  22. 22.
    Mahner S, Baasch C, Schwarz J, Hein S, Wölber L, Jänicke F, Milde-Langosch K (2008) c-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer 99:1269–1275. CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Bradford MM (1976) A rapid and sensitivemethod for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254CrossRefGoogle Scholar
  24. 24.
    Sung WW, Lin YM, Wu PR, Yen HH, Lai HW, Su TC, Huang RH, Wen CK, Chen CY, Chen CJ, Yeh KT (2014) High nuclear/cytoplasmic ratio of Cdk1expressionpredictspoorprognosis in colorectal cancer patients. BMC Cancer 14:951. CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC(T)) Method. Methods 25:402–408. CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Koliopanos A, Kleeff J, Xiao Y, Safe S, Zimmermann A, Büchler MW, Friess H (2002) Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. Oncogene 21:6059–6070. CrossRefPubMedGoogle Scholar
  27. 27.
    Gluschnaider U, Hidas G, Cojocaru G, Yutkin V, Ben-Neriah Y, Pikarsky E (2010) beta-TrCP inhibition reduces prostate cancer cell growth via upregulation of the aryl hydrocarbon receptor. PLoS ONE 5:e9060. CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Ishida M, Mikami S, Kikuchi E, Kosaka T, Miyajima A, Nakagawa K, Mukai M, Okada Y, Oya M (2010) Activation of the aryl hydrocarbon receptor pathway enhances cancer cell invasion by upregulating the MMP expression and is associated with poor prognosis in upper urinary tract urothelial cancer. Carcinogenesis 31:287 – 95. CrossRefPubMedGoogle Scholar
  29. 29.
    Yang X, Solomon S, Fraser LR, Trombino AF, Liu D, Sonenshein GE, Hestermann EV, Sherr DH (2008) Constitutive regulation of CYP1B1 by the aryl hydrocarbon receptor (AhR) in pre-malignant and malignant mammary tissue. J Cell Biochem 104:402 – 17. CrossRefPubMedGoogle Scholar
  30. 30.
    Lin P, Chang H, Tsai WT, Wu MH, Liao YS, Chen JT, Su JM (2003) Overexpression of aryl hydrocarbon receptor in humanlungcarcinomas. Toxicol Pathol 31:22–30CrossRefGoogle Scholar
  31. 31.
    Gramatzki D, Pantazis G, Schittenhelm J, Tabatabai G, Köhle C, Wick W, Schwarz M, Weller M, Tritschler I (2009) Aryl hydrocarbon receptor inhibition downregulates the TGF-b/Smad pathway in human glioblastoma cells. Oncogene 28:2593–2605. CrossRefPubMedGoogle Scholar
  32. 32.
    Hayashibara T, Yamada Y, Mori N, Harasawa H, Sugahara K, Miyanishi T, Kamihira S, Tomonaga M (2003) Possible involvement of aryl hydrocarbon receptor (AhR) in adult T-cell leukemia (ATL) leukemogenesis: constitutive activation of AhR in ATL. Biochem Biophys Res Commun 300:128 – 34CrossRefGoogle Scholar
  33. 33.
    Bosnyak E, Kamson DO, Guastella AR, Varadarajan K, Robinette NL, Kupsky WJ, Muzik O, Michelhaugh SK, Mittal S, Juhász C (2015) Molecular imaging correlates of tryptophan metabolism via the kynurenine pathway in human meningiomas. Neuro-oncology 17:1284–1292. CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Zitron IM, Kamson DO, Kiousis S, Juhász C, Mittal S (2013) In vivo metabolism of tryptophan in meningiomas is mediated by indoleamine 2,3-dioxygenase 1. Cancer Biol Ther 14:333–339. CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Stavrinou P, Mavrogiorgou MC, Polyzoidis K, Kreft-Kerekes V, Timmer M, Marselos M, Pappas P (2015) Expression profile of genes related to drug metabolism in human brain tumors. PLoS ONE 10:e0143285. CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Bui LC, Tomkiewicz C, Chevallier A, Pierre S, Bats AS, Mota S, Raingeaud J, Pierre J, Diry M, Transy C, Garlatti M, Barouki R, Coumoul X (2009) Nedd9/Hef1/Cas-L mediates the effects of environmental pollutants on cell migration and plasticity. Oncogene 28:3642–3651. CrossRefPubMedGoogle Scholar
  37. 37.
    Kong B, Wu W, Cheng T, Schlitter AM, Qian C, Bruns P, Jian Z, Jäger C, Regel I, Raulefs S, Behler N, Irmler M, Beckers J, Friess H, Erkan M, Siveke JT, Tannapfel A, Hahn SA, Theis FJ, Esposito I, Kleeff J, Michalski CW (2016) A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling. Gut 65:647–657. CrossRefPubMedGoogle Scholar
  38. 38.
    Jia J, Parikh H, Xiao W, Hoskins JW, Pflicke H, Liu X, Collins I, Zhou W, Wang Z, Powell J, Thorgeirsson SS, Rudloff U, Petersen GM, Amundadottir LT (2013) An integrated transcriptome and epigenome analysis identifies a novel candidate gene for pancreatic cancer. BMC Med Genom 6:33. CrossRefGoogle Scholar
  39. 39.
    Saw YT, Yang J, Ng SK, Liu S, Singh S, Singh M, Welch WR, Tsuda H, Fong WP, Thompson D, Vasiliou V, Berkowitz RS, Ng SW (2012) Characterization of aldehyde dehydrogenase isozymes in ovarian cancer tissues and sphere cultures. BMC Cancer 12:329. CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S, Giacomantonio CA, Lee PW (2011) Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 29:32–45. CrossRefPubMedGoogle Scholar
  41. 41.
    Nebert DW, Dalton TP, Okey AB, Gonzalez FJ (2004) Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 279:23847–23850. CrossRefPubMedGoogle Scholar
  42. 42.
    Meng FD, Ma P, Sui CG, Tian X, Jiang YH (2015) Association between cytochrome P4501A1 (CYP1A1) genepolymorphisms and the risk of renal cell carcinoma: a meta-analysis. Sci Rep 5:8108. CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Ding G, Xu W, Liu H, Zhang M, Huang Q, Liao Z (2013) CYP1A1 MspI polymorphism is associated with prostate cancer susceptibility: evidence from a meta-analysis. Mol Biol Rep 40:3483–3491. CrossRefPubMedGoogle Scholar
  44. 44.
    Gong FF, Lu SS, Hu CY, Qian ZZ, Feng F, Wu YL, Yang HY, Sun YH (2014) Cytochrome P450 1A1 (CYP1A1) polymorphism and susceptibility to esophageal cancer: an updated meta-analysis of 27 studies. Tumor Biol 35:10351–10361. CrossRefGoogle Scholar
  45. 45.
    Sergentanis TN, Economopoulos KP, Choussein S, Vlahos NF (2012) Cytochrome P450 1A1 (CYP1A1) gene polymorphisms and cervical cancer risk: a meta-analysis. Mol Biol Rep 39:6647–6654. CrossRefPubMedGoogle Scholar
  46. 46.
    Liu L, Wu G, Xue F, Li Y, Shi J, Han J, Zhang X, Na Y, Zhang H, Tang X, Pu H, Yuan Q, Zhang L, Yang M (2013) Functional CYP1A1 genetic variants, alone and in combination with smoking, contribute to development of head and neck cancers. Eur J Cancer 49:2143–2151. CrossRefPubMedGoogle Scholar
  47. 47.
    Teng CS (2000) Proto-oncogenes as mediators of apoptosis. Int Rev Cytol 197:137–202CrossRefGoogle Scholar
  48. 48.
    Mikula M, Gotzmann J, Fischer AN, Wolschek MF, Thallinger C, Schulte-Hermann R, Beug H, Mikulits W (2003) The proto-oncoprotein c-Fos negatively regulates hepatocellular tumorigenesis. Oncogene 22:6725–6738. CrossRefPubMedGoogle Scholar
  49. 49.
    Wang X, Gong Y, Wang D, Xie Q, Zheng M, Zhou Y, Li Q, Yang Z, Tang H, Li Y, Hu R, Chen X, Mao Y (2012) Analysis of gene expression profiling in meningioma: deregulated signaling pathways associated with meningioma and EGFL6 over expression in benign meningioma tissue and serum. PLoS ONE 7:e52707. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Biotechnology & Bioinformatics, School of Life SciencesUniversity of HyderabadHyderabadIndia
  2. 2.Department of NeurosurgeryKIMSSecunderabadIndia
  3. 3.Laboratory of Neurochemistry, Department of Biotechnology & Bioinformatics, School of Life sciencesUniversity of HyderabadHyderabadIndia

Personalised recommendations